Company News 

Seven Days: 24 July 2020

Seven Days: 24 July 2020

Vaccine progress

Positive trial data

A Covid-19 vaccine being developed by Oxford University and AstraZeneca (AZN) has achieved positive results in early-stage trials. Data from the phase one and phase two trial – which have been published in the scientific journal The Lancet – revealed a T-cell and antibody response to the vaccine candidate. The trial results, which centred on just over 1,000 healthy adult participants, suggested that the vaccine did not induce any unexpected reactions. The trial is one of several taking place across the globe, as the scientific community works at unprecedented speeds to fight the coronavirus pandemic.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now